EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSACLG00000019733
Gene Symbol: GRIN3B
3 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSACLG00000024732
Gene Symbol: GRIK1
1 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSACLG00000001838
Gene Symbol: GRIK1
1 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSACLG00000006480
Gene Symbol: GRIK2
4 Cross references
243 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSACLG00000027806
Gene Symbol: GRIK3
4 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSACLG00000019735
Gene Symbol: GRIK4
3 Cross references
247 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSACLG00000026152
Gene Symbol: GRIK5
3 Cross references
263 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSACLG00000010861
Gene Symbol: GRIK5
3 Cross references
258 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSACLG00000023629
Gene Symbol: GRM2
3 Cross references
210 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSACLG00000000676
Gene Symbol: GRM4
3 Cross references
214 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSACLG00000023565
Gene Symbol: GRM5
3 Cross references
216 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSACLG00000026066
Gene Symbol: LOC113030115
3 Cross references
249 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).